Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160037/S028

BD Onclarity HPV Assay

Becton Dickinson and Company · Decision date Aug 14, 2026

FDA DECISIONP160037/S028

What did the FDA approve?

FDA records P160037/S028 as a supplement to PMA P160037, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Aug 14, 2026.

FDA approval order statement

Approval for the extension of self-collected vaginal specimen transport and storage conditions for the BD Onclarity HPV Assay.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Microbiology
Decision date
Aug 14, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P160037/S028
Regulatory pathway
PMA supplement
Product code
MAQ
Decision code
APPR
Decision date
Aug 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.

Product code
MAQ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P160037/S026 · Related supplement

    BD FOX PCR Extraction Tubes; BD Onclarity HPV Assay

  2. P160037/S028 received

    Application receipt date recorded by FDA.

  3. P160037/S028 · FDA decision

    Real-Time Process

  4. P160037/S027 · Related supplement

    BD Onclarity HPV Assay Reagent Pack (SKU 444075) and BD COR HPV Extraction Trough (SKU 444074)

Timeline entries are records held by MedtechLedger for P160037. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160037

Product / regulatory recordCompanyPathwayDecision dateSource
Becton Dickinson and CompanyPMA supplementAug 25, 2025FDA
Becton Dickinson and CompanyPMA supplementFeb 12, 2026FDA
Becton Dickinson and CompanyPMA supplementApr 2, 2026FDA
Becton Dickinson and CompanyPMA supplementApr 2, 2026FDA
Becton Dickinson and CompanyPMA supplementAug 19, 2026FDA

Explore the linked device profile

Other records with product code MAQ

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HPVP100020/S066
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
cobas HPVP190028/S026
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Alinity m HR HPVP230003/S019
Abbott Molecular, Inc.PMA supplementSep 2, 2026FDA
Alinity m HR HPVP230003/S015
Abbott Molecular, Inc.PMA supplementJul 23, 2026FDA
Alinity m HR HPVP230003/S018
Abbott Molecular, Inc.PMA supplementJun 22, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Becton Dickinson and Company

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7loveton Cir., Sparks, MD, 21152

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records